T-cell Engagers Market to Record US$ 58.04 billion by 2035.
The global T-cell Engagers Market is projected to reach US$ 58.04 billion by 2035, growing at a CAGR of 22.73% from its 2025 valuation of US$ 7.27 billion. Key industry developments include advancements in BiTE platforms, expansion of manufacturing capabilities, and strategic collaborations among major pharmaceutical companies like Amgen, Johnson & Johnson, and Regeneron. The market's growth is driven by increasing adoption, investments, and innovations in oncology immunotherapy and autoimmune disease treatments across various regions.
Xencor Inc stock (US98401F1057): JPMorgan lifts target while investors eye Q1 2026 update
JPMorgan Chase & Co. has raised its price target for Xencor Inc. to $14 per share, following the biotech company's release of its first-quarter 2026 financial results. Xencor, a clinical-stage biopharmaceutical company focused on antibody and protein therapeutics, relies on collaboration revenues, milestone payments, and royalties from partners, while also developing its own oncology and autoimmune candidates. The stock experienced volatility, closing at $11.22 on May 15, 2026, highlighting the sensitivity of development-stage biotechs to news flow and clinical progress.
Xencor, Inc. $XNCR Shares Sold by UBS Group AG
UBS Group AG significantly reduced its holdings in Xencor, Inc. (NASDAQ:XNCR) by 45.7% in the fourth quarter, selling over 537,000 shares. This comes as Xencor reported a substantial miss on earnings estimates and an 86.2% year-over-year revenue decrease. Analyst sentiment for Xencor is mixed but leaning cautious, with recent downgrades counteracted by some higher price targets, resulting in a current "Hold" average rating.
EcoR1 reports 2.9% Xencor stake (NASDAQ: XNCR)
EcoR1 Capital, LLC, along with related filers, has reported a beneficial ownership of 2.9% in Xencor Inc. (NASDAQ: XNCR), totaling 2,183,000 shares. A separate entity, EcoR1 Capital Fund Qualified, L.P., holds 2.8%, or 2,041,033 shares. These percentages are calculated based on 71,141,596 shares outstanding as of May 1, 2026, and the filing clarifies that these stakes do not intend to change, or influence control of, Xencor.
Xencor stock (US98401F1057): Biotech focus on immunotherapy and protein engineering
Xencor Inc. (XNCR) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy candidates for cancer treatment using proprietary protein engineering technology. The company's business model relies on advancing its pipeline through clinical development and securing regulatory approvals, with revenue expected from commercialization and partnerships. Investors are advised to monitor clinical trial progress, partnership announcements, and capital management as key indicators for this volatile stock in the competitive immunotherapy market.
Xencor stock (US98401F1057): Biotech innovator in antibody therapies
Xencor Inc. (XNCR) is a biotechnology company specializing in developing bispecific antibodies and protein therapeutics for cancer and autoimmune diseases, leveraging its proprietary XmAb platform. The company's business model relies on internal pipeline development and strategic partnerships with major pharmaceutical firms, generating revenue through upfront payments, milestones, and royalties. Xencor continues to advance its clinical programs, targeting unmet medical needs and offering investors exposure to innovation in the evolving immunotherapy landscape.
Xencor Is Maintained at Neutral by JP Morgan
JP Morgan has maintained its Neutral rating on Xencor. The article does not provide further details regarding the rationale behind this rating or any financial analysis.
Xencor (NASDAQ:XNCR) Price Target Raised to $14.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for Xencor (NASDAQ:XNCR) to $14.00 from $13.00, maintaining a "neutral" rating on the biopharmaceutical stock despite previous weak quarterly results. The new target suggests a potential upside of 9.25% from the current share price. Analyst opinions on Xencor are mixed, with an average "Hold" rating and a consensus price target of $24.50 across various firms.
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
Analysts have significantly downgraded their near-term forecasts for Xencor, Inc. (NASDAQ:XNCR), anticipating a substantial decline in revenue and increased losses per share for 2026. This pessimistic outlook suggests a clear change in sentiment towards the biopharmaceutical company, whose revenues have already been declining over the past five years. Despite the downgrades, the consensus price target remains unchanged, though the worsening business conditions could impact the stock price.
Xencor (NASDAQ:XNCR) Rating Lowered to Strong Sell at Wall Street Zen
Xencor (NASDAQ:XNCR) has been downgraded to a "Strong Sell" rating by Wall Street Zen, adding to a mixed analyst outlook that includes a consensus "Hold" rating and a target price of $24.38. This downgrade follows the company's significantly worse-than-expected quarterly loss of ($1.71) EPS against an anticipated ($0.75), and revenue of $4.52 million, which fell well below estimates and represented an 86.2% year-over-year decline. The article also notes continued insider selling despite a recent 4.5% stock price increase, with analysts expecting a full-year loss for Xencor.
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor, Inc. announced final results from its Phase 1 study of XmAb942, an anti-TL1A antibody for inflammatory bowel disease, which support its potential as a best-in-class treatment. The company also presented preclinical data for XmAb412, a novel bispecific antibody, and plans a first-in-human study for Q3 2026. Xencor will host a webcast on May 5th to discuss these data presentations and their implications for the treatment of autoimmune and inflammatory diseases.
Xencor (XNCR) Q1 Loss Surges To US$128.9 Million Challenging Bullish Growth Narratives
Xencor (XNCR) reported a significant Q1 2026 net income loss of US$128.9 million on just US$4.5 million in revenue, a notable increase in losses compared to previous quarters. Despite analyst forecasts for future revenue growth, the company remains unprofitable and is not expected to achieve profitability in the next three years. This challenging financial performance creates tension with bullish growth narratives and highlights concerns around competition, funding risk, and prolonged unprofitability.
Xencor, Inc. (XNCR) Stock Analysis: Exploring A 132% Potential Upside In Biotech
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases, showing a potential upside of 132.20% according to analysts. Despite current financial challenges such as a negative forward P/E and declining revenue, the company's innovative pipeline and strong analyst support suggest significant long-term growth potential. Investors are advised to consider the high risks associated with clinical-stage biotech but also the possibility of substantial stock appreciation through successful clinical trials and regulatory approvals.
Xencor (NASDAQ:XNCR) Downgraded by Zacks Research to "Strong Sell"
Zacks Research has downgraded Xencor (NASDAQ:XNCR) from a "hold" to a "strong sell" rating. This comes after Xencor reported a significant quarterly miss, with EPS of ($1.71) against an expected ($0.75) and revenue of $4.52 million compared to an expected $27.86 million, marking an 86.2% year-over-year decline. Despite insider selling, large institutional investors have increased their holdings in the biopharmaceutical company.
Xencor (XNCR) Q1 Loss Surges To US$128.9 Million Challenging Bullish Growth Narratives
Xencor (XNCR) reported a significant Q1 2026 net income loss of US$128.9 million on just US$4.5 million in revenue, widening losses compared to previous quarters. Despite analysts forecasting 35.9% annual revenue growth, the company remains unprofitable and is not expected to reach profitability in the next three years. This performance creates tension with bullish growth narratives and raises concerns for investors about funding risk and prolonged unprofitability.
Xencor (NASDAQ: XNCR) posts deeper Q1 2026 loss amid royalty dispute and Zenas write-down
Xencor (NASDAQ: XNCR) reported a significantly wider loss in Q1 2026, with revenue dropping to $4.5 million from $32.7 million year-over-year. This was primarily due to a lack of repeating Incyte milestones, reduced Ultomiris royalty revenue, and a $51.9 million unrealized loss on its equity stake in Zenas BioPharma. The company is also engaged in a royalty dispute with Alexion concerning Ultomiris U.S. payments, leading to a reversal of $6.6 million in previously recorded royalties.
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) reported a wider-than-expected Q1 loss of $1.71 per share, significantly missing the Zacks Consensus Estimate of a $0.65 loss, and also lagged revenue estimates with $4.52 million against an expected 75.38% higher figure. Despite beating EPS estimates three times in the last four quarters, the revenue performance was a miss for the quarter ended March 2026. The stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
Number of shareholders of Xencor, Inc. – MUN:XE9
This article provides concise information about the number of shareholders for Xencor, Inc. (MUN:XE9). It indicates that the period value and change percentages for shareholders are available. The content is primarily a listing within a market data platform.
Earnings Flash (XNCR) Xencor, Inc. Reports Q1 Revenue $4.5M
Xencor, Inc. reported its first-quarter revenue of $4.5 million, with the earnings flash coming out on May 6, 2026. This announcement also includes subsequent news updates regarding their Phase 1 study results and a recent downgrade by JPMorgan, alongside other corporate news and financial data. The company is a clinical-stage biopharmaceutical firm developing engineered antibodies for cancer and autoimmune diseases.
Xencor (NASDAQ:XNCR) Releases Earnings Results, Misses Estimates By $1.06 EPS
Xencor (NASDAQ:XNCR) reported earnings results, missing analyst estimates significantly with an EPS of ($1.71) against a consensus of ($0.65) and revenue of $4.52 million compared to an expected $27.86 million. The biopharmaceutical company also reported negative net margin and return on equity. The stock is currently rated a "Moderate Buy" by analysts with a consensus target price of $24.38, despite recent insider share sales.
Xencor (NASDAQ: XNCR) Q1 loss widens as revenue and royalties fall
Xencor reported significantly weaker financial results for Q1 2026, with revenue dropping sharply to $4.5 million from $32.7 million in the prior year, partly due to a one-time $6.6 million reduction from disputed Alexion royalties. The company's net loss widened to $128.9 million, or $(1.71) per share, compared to a $48.4 million loss, or $(0.66) per share, in Q1 2025, driven by increased R&D spending and unrealized losses on an equity security. Despite the widened loss, Xencor maintains a strong liquidity position with $541.8 million in cash as of March 31, 2026, expecting this to fund operations and R&D into mid-2028.
Xencor Reports First Quarter 2026 Financial Results
Xencor, Inc. reported its financial results for the first quarter ended March 31, 2026, highlighting significant progress in its oncology and autoimmune disease clinical pipelines. Key updates include plans to present XmAb819 data for clear cell renal cell carcinoma in late 2026, initiation of a Phase 1 study for XmAb412 in Q3 2026, and continued advancement of XmAb942 in ulcerative colitis. The company ended the quarter with $541.8 million in cash and expects to fund operations into mid-2028.
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - Slideshow
Xencor, Inc. (XNCR) has released a slide deck discussing the Phase I results for its experimental drug XmAb942. The company also presented preclinical data for another compound, XmAb412. This information was published on May 05, 2026, and is available for review, likely detailing the progress and potential of these therapeutic candidates.
Behavioral Patterns of XNCR and Institutional Flows
The article analyzes Xencor Inc. (NASDAQ: XNCR) using AI models, indicating a neutral near and mid-term outlook but a strong long-term positive bias. It highlights a unique 98.3:1 risk-reward setup targeting a 25.6% gain with minimal risk. Three distinct institutional trading strategies are provided: a long position trading strategy, a momentum breakout strategy, and a risk-hedging short strategy, complete with entry, target, and stop-loss zones.
Xencor Highlights TL1A Autoimmune Portfolio and IBD Strategy
Xencor highlighted its TL1A-focused autoimmune portfolio, including final Phase 1 XmAb942 data and preclinical results for XmAb412, positioning them as potential best-in-class therapies for inflammatory bowel disease (IBD). The company outlined a robust clinical roadmap for 2026–2027 for both autoimmune and oncology programs, aiming to capture a significant share in the expanding IBD biologics market. Xencor emphasized the advanced engineering of its candidates for improved efficacy and dosing convenience, despite a "Neutral" rating from TipRanks' AI Analyst due to weak financial performance.
Xencor presents Phase 1 XmAb942 final results; XmAb412 FIH study on track for 3Q26
Xencor (NEXR) announced the final results from its Phase 1 study of XmAb942, indicating it is well tolerated with a long half-life supporting quarterly maintenance dosing. Additionally, the company is on track to begin a first-in-human study for XmAb412 in the third quarter of 2026, with preclinical data showing potent suppression of TL1A and IL23. The XENITH-UC Phase 2b trial is also progressing, with interim analysis expected around year-end 2026.
Xencor (XNCR) expands TL1A franchise with XmAb942 data and XmAb412 moving to clinic
Xencor announced positive Phase 1 data for XmAb942, an anti-TL1A antibody for inflammatory bowel disease, showing it was well-tolerated with an extended half-life supporting 12-week dosing. The company also detailed its bispecific antibody XmAb412 (TL1A x IL23p19), which demonstrated high potency and is slated for a first-in-human study in Q3 2026. These developments reinforce Xencor's strategy to build a leading TL1A-focused autoimmune franchise, with key clinical readouts expected through 2027.
Xencor to host webcast to discuss XmAb942, XmAb412 data presentations
Xencor will host a webcast to discuss the final results of its Phase 1 study for XmAb942, a long-acting anti-TL1A antibody for inflammatory bowel disease, and preclinical data for XmAb412, a novel bispecific antibody. The Phase 1 XmAb942 results indicate a potential best-in-class profile, showing enhanced TL1A inhibition and good tolerability. Enrollment for the Phase 2b XENITH-UC study of XmAb942 is on track, and a first-in-human study for XmAb412 is expected to begin in Q3 2026.
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor will host a webcast to discuss new data on its lead product candidates, XmAb942 and XmAb412, which were presented at Digestive Disease Week (DDW). Final Phase 1 results for XmAb942, an anti-TL1A antibody for inflammatory bowel disease, support its potential as a best-in-class treatment, while preclinical data for XmAb412, a novel bispecific antibody, highlight its potential for autoimmune diseases. The company expects to start a first-in-human study for XmAb412 in Q3 2026 and anticipates interim results for the XmAb942 Phase 2b study by year-end 2026.
Xencor (XNCR) Projected to Post Earnings on Wednesday
Xencor (NASDAQ:XNCR) is expected to announce its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts forecasting an EPS of ($0.65) and revenue of $27.855 million. The biopharmaceutical company recently reported a beat on EPS in the previous quarter but saw revenue decline. Shares are currently trading down approximately 7.3%, and the company holds a "Moderate Buy" consensus rating from analysts with an average target price of $24.38.
Xencor Adopts Executive Severance Policy to Support Retention
Xencor, Inc. has adopted an Executive Severance Policy for senior executives, excluding the CEO, to support retention and corporate stability. The policy outlines severance benefits for various termination scenarios, including lump-sum payments, COBRA premiums, and accelerated equity vesting during a change-in-control period. This move aims to formalize executive protections and enhance stakeholder confidence, though an AI analyst rates Xencor (XNCR) as "Neutral" due to weak financial performance and bearish technicals.
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Xencor, Inc. (NASDAQ:XNCR) has received a "Moderate Buy" consensus rating from nine analysts, with an average 12-month price target of $24.38; however, individual analyst opinions range from "overweight" to "neutral" and "sell." The company experienced mixed financial performance, beating EPS expectations but seeing a 46.6% year-over-year revenue decline and remaining unprofitable. While company insiders have recently sold shares, several institutional investors have increased their stakes in Xencor.
Xencor Gears Up For DDW 2026 Readouts, 2H26 Pipeline Catalysts
Xencor, Inc. (XNCR) is set to present new data at Digestive Disease Week (DDW) 2026, scheduled for May 2-5, 2026, and anticipates multiple readouts and trial starts in the second half of 2026. The biopharmaceutical company will share final results from its Phase 1 healthy-volunteer study of XmAb942, an extended half-life anti-TL1A antibody, and preclinical data for XmAb412, a bispecific antibody targeting inflammatory pathways. These upcoming events are significant catalysts for the company as it develops engineered antibodies for cancer and autoimmune diseases.
Xencor (NASDAQ:XNCR) Stock Passes Above 50 Day Moving Average - Time to Sell?
Xencor (NASDAQ:XNCR) stock has recently moved above its 50-day moving average, trading at $13.10, but below its 200-day moving average. Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $24.38, despite recent mixed revisions and insider selling. The company reported better-than-expected EPS but missed revenue forecasts and remains unprofitable.
Xencor trying to close in on key technical benchmark
This article from MSN suggests that Xencor (XNCR) is approaching a significant technical benchmark. The content provided is minimal, so further details are unavailable regarding what this benchmark entails or its potential implications for the company.
Xencor Inc SEC Filing
This article announces an SEC filing of Form ARS by Xencor Inc. (XNCR) on April 27, 2026. The filing is categorized as having a low impact and neutral sentiment, and the full document is available in PDF format via SEC EDGAR. The article also provides a brief overview of Xencor Inc., including its market cap, industry, and recent news and SEC filings.
Xencor (NASDAQ: XNCR) seeks approval for 4M new equity plan shares and auditor
Xencor, Inc. is requesting stockholder approval for several key items at its annual meeting on June 16, 2026. These include an amendment to its 2023 Equity Incentive Plan to add 4 million shares, ratifying KPMG LLP as the auditor for 2026, and electing nine directors. The company ended 2025 with $610.8 million in cash and highlighted progress in its oncology and autoimmune disease pipelines.
Executive severance plan at Xencor (NASDAQ: XNCR) adds change-in-control terms
Xencor, Inc. (NASDAQ: XNCR) has adopted a new Executive Severance Policy for its named executive officers, excluding the CEO, to provide severance benefits under specific termination conditions. The policy includes enhanced benefits during a change-in-control period, such as accelerated equity vesting and additional bonus compensation, in addition to standard severance pay and COBRA coverage. Eligible executives must sign a participation agreement to receive these benefits.
(XNCR) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Xencor Inc. (NASDAQ: XNCR), indicating a neutral near and mid-term outlook that could moderate a long-term positive bias. It highlights a significant short setup with a 73.3:1 risk-reward ratio and outlines specific institutional trading strategies including long, breakout, and risk hedging plays. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for the stock.
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Xencor (NASDAQ:XNCR) from a "sell" to a "hold" rating after the biopharmaceutical company reported Q1 earnings that beat EPS estimates but missed revenue expectations. Despite a "Moderate Buy" consensus rating from analysts, recent insider transactions show executives selling shares. The company, which is clinical-stage and focuses on engineered protein therapeutics, remains unprofitable with a negative net margin and ROE.
Xencor CFO Cornelissen sells $42990 in stock By Investing.com
Xencor's CFO, Bart Jan Cornelissen, sold 3,499 shares of common stock for $42,990 on April 10, 2026, to cover withholding taxes from restricted stock unit vesting, retaining 75,898 shares. The company is also dealing with a royalty dispute with Alexion Pharmaceuticals and a downgrade from JPMorgan, though Truist Securities reiterated a Buy rating due to momentum in the TL1A×IL-23p bispecifics sector.
Xencor (XNCR) CFO sells 3,499 shares to cover tax on vested RSUs
Xencor Inc.'s Senior Vice President and CFO, Bart Jan Cornelissen, sold 3,499 shares of common stock on April 10, 2026, at an average price of $12.2865 per share. This transaction was specifically to cover withholding taxes upon the vesting of 14,088 restricted stock units, and not an open-market sale. After the sale, Cornelissen directly held 75,898 shares of Xencor common stock.
Xencor CFO Cornelissen sells $42990 in stock
Xencor CFO Bart Jan Cornelissen sold 3,499 shares of common stock for $42,990 to cover withholding taxes. This transaction occurred amidst a royalty dispute between Xencor and Alexion Pharmaceuticals regarding Ultomiris sales, a downgrade from JPMorgan, and a reiterated Buy rating from Truist Securities due to momentum in the TL1A×IL-23p bispecifics sector.
How (XNCR) Movements Inform Risk Allocation Models
This article analyzes Xencor Inc. (NASDAQ: XNCR) stock movements, highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 97.3:1 risk-reward setup targeting a 25.6% gain versus 0.3% risk. The piece also outlines specific AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
[144] Xencor Inc SEC Filing
This SEC Form 144 filing from Xencor Inc. (XNCR) indicates the proposed sale of 3,499 shares of common stock resulting from restricted stock vesting on April 9, 2026. The filing also documents a prior sale of 2,517 shares on March 5, 2026, by Bart Jan Cornelissen. The total aggregate market value of the shares to be sold is $42,990.46.
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $24.38. Despite beating Q4 EPS estimates, the company's revenue fell 46.6% year-over-year, and it remains unprofitable. Insider activity shows recent sales by the CEO and a VP, totaling approximately $499,817 over the past 90 days.
Xencor sr. VP Desjarlais sells $31,676 in stock
Xencor's Sr. Vice President & CSO, John R Desjarlais, sold 2,663 shares of common stock for $31,676. This transaction occurred on March 3, 2026, alongside acquisitions of restricted stock units and options. The company is also managing a royalty dispute with Alexion Pharmaceuticals and received a reiterated Buy rating from Truist Securities.
Xencor SVP Eckert sells $17,747 in shares
Celia Eckert, SVP and General Counsel of Xencor Inc. (NASDAQ: XNCR), sold 1,492 shares for a total of $17,747. This sale occurred after acquiring 18,680 shares for $0 and being granted options for 112,080 shares with a vesting schedule. The company is noted as undervalued by InvestingPro, holding more cash than debt but also burning through cash rapidly.
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving Average - What's Next?
Xencor (NASDAQ:XNCR) shares recently fell below their 200-day moving average, trading as low as $11.17 before settling at $12.06. Analyst ratings are mixed, with a "Moderate Buy" consensus but some downgrades and price target cuts, including by JPMorgan. Despite beating EPS estimates, the company's revenue dropped significantly year-over-year, and insiders have been selling shares.
RA Capital, insiders report shared 6.5% stake in Xencor (NASDAQ: XNCR)
A Schedule 13G filing reveals that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah collectively hold a shared beneficial ownership of 4,736,739 shares in Xencor, Inc. (NASDAQ: XNCR). This stake represents 6.5% of Xencor's common stock, based on 73,338,642 shares outstanding as of February 17, 2026. The filing explicitly states that the Reporting Persons disclaim group status for Section 13(d) purposes, and the fund has delegated voting and dispositive powers to RA Capital, revocable on 61 days' notice.
